T h i r d Q u a r t e r 2 0 2 5 E a r n i n g s P r e s e n t a t i o n November 12, 2025 Di scl aime rs Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. KORE's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statement ...

Financial Performance & Construction - Sky Harbour's construction is accelerating, leading to increasing revenues[23] - Sky Harbour Capital LLC raised capital through a municipal bond offering[8] - As of Q3 2025, Sky Harbour has approximately $247.9 million in US Treasuries and cash, including $36.473 million in cash and $11.447 million in treasuries, along with a $200 million warehouse facility[69] - A $200 million JP Morgan draw down facility is funding construction of BDL, SLC, POU1, ORL1, and TTN, swapped to a fixed interest rate of 4.73%[65, 66] Site Acquisition & Development - Sky Harbour reaffirms guidance of 4 new airport announcements by year-end 2025, targeting a total of 23 airports[51] - Sky Harbour is expanding into the Tier 1 LA market with the Long Beach Airport (LGB) project, featuring a 196k SF campus across 2 phases, with potential stabilized revenue of $10 million[54, 56] - Sky Harbour has 19 airport ground leases and is pursuing same-field expansion opportunities, targeting Tier-1 Airports[76] - The company has commenced construction on new sites and is preparing for a surge in development in 2026 and 2027[76, 82] Leasing & Operations - Stabilized campuses are showing revenue growth post-stabilization[76] - Sky Harbour has adopted a preleasing strategy, starting with BDL, to enhance long-term revenue[76, 82] - The company is focused on bringing new campuses to 100% occupancy and establishing market rents[82]

Financial Performance - Gross revenue increased from $0.25 million to $0.69 million for the three months ended September 30, 2025 [35] - Net revenue increased from $0.60 million to $1.63 million for the nine months ended September 30, 2025 [35] - Net loss was $5.2 million for the three months ended September 30, 2025 [35] - Total Remaining Performance Obligation (RPO) decreased from $14.3 million to $3.6 million [36] - Booked Annual Recurring Revenue (bARR) was $2.35 million for the nine months ended September 30, 2025 [37] Business Highlights - Q3 contract bookings included a top 10 global supermarket retailer and NEC Networks & System Integration Corp [9] - The company is engaged with prospects ranked in the top 10 leaders in their industries [13] - authID's ID Verification and Privacy-Preserving Biometrics are used for NESIC's Symphonict Trust Platform [16] - authID is powering Prove's Unified fraud platform with PrivacyKey's 1:1Billion signal [16] - authID co-developed and launched IDProof+, a High Assurance Identity Verification solution combining AuthID's Proof with Microsoft Entra Verified ID [16] Strategic Positioning - The company is positioned to capitalize on the market shift to biometrics due to increasing fraud and the rise of AI [29, 32] - authID is innovating to solve for enterprise adoption by integrating privacy-preserving biometrics [17] - The company is focused on securing new customer contracts, establishing contractual commitments, recognizing revenue, and retaining/expanding customer relationships [38]

Financial Performance - Revenue reached R$2,784.3 million, a 13.4% year-over-year increase for the nine-month period[7] - Adjusted EBITDA was R$1,291.7 million, up 18.5% year-over-year, with an adjusted EBITDA margin of 46.4%, a 200 bps increase[7] - Net income increased by 19.9% year-over-year to R$593.0 million, with earnings per share at R$6.40, a 19.7% increase[7] - Cash flow from operating activities increased by 10.6% year-over-year to R$1,291.5 million, with an operating cash conversion ratio of 101.5%[7] Operational Metrics - Medical school students totaled 25,706 at the end of the period[7] - Approved medical school seats reached 3,653[7] - Continuing education revenue increased by 10.6% year-over-year to R$207.6 million[7] - Medical practice solutions revenue increased by 9.3% year-over-year to R$128.2 million[7] Debt and Liabilities - New debenture issuance of R$1.5 billion to fund repurchase of preferred shares and prepay first debenture issuance[36, 37] - Total gross debt was R$2,339 million[38] ESG Initiatives - Delivered 700,000 free healthcare consultations, including over 500,000 medical consultations[10]

Financial Performance - Total revenue for Q3 2025 reached $126 million, an 18% increase compared to $107 million in Q3 2024[42] - Subscription revenue for Q3 2025 was $113 million, a 21% increase from $93 million in Q3 2024[42] - ARR (Annual Recurring Revenue) as of September 2025 reached $440 million, a 19% increase compared to $371 million in September 2024[42] - Adjusted EBITDA for Q3 2025 was $38 million, representing 30% of revenue, compared to $31 million and 29% in Q3 2024[42] - The company anticipates ARR to be between $460 million and $475 million for fiscal year 2025, representing a growth of 16% to 20%[72] - The company expects revenue to be between $470 million and $475 million for fiscal year 2025, representing a growth of 17% to 18%[72] - The company projects adjusted EBITDA to be between $124 million and $127 million for fiscal year 2025, with an adjusted EBITDA margin of 26% to 27%[72] Acquisition - Cellebrite is set to acquire Corellium for $170 million in cash, with an additional $30 million earn-out potential over 2 years, the deal is expected to close in Q4 2025[34] Market Position - Cellebrite has a global customer base of approximately 7,000 customers[8] - Cellebrite's solutions are used in over 1.5 million legally-sanctioned investigations in 2024[8] - Cellebrite serves over 3,000 state and local accounts in North America, including 72 out of the top 100[24]

Allogene Corporate Overview November 2025 Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent that statements contained in this presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statem ...

Financial Performance - KORU Medical Systems achieved record Q3 revenues of $10.4 million, a 27% increase compared to the prior year period, driven by the Core SCIg business[6, 20] - The company reported a net loss of $0.8 million but achieved a positive adjusted EBITDA of $0.09 million and generated $0.4 million in cash during Q3[6] - KORU Medical Systems is raising its 2025 revenue guidance to $40.5-$41.0 million, representing a growth of 20%-22%, and reiterating a gross margin of 61%-63%[6] Market and Growth Opportunities - The US SCIg market is forecasted to grow at 9%+ through 2029[8] - KORU Medical Systems has grown its international market share from approximately 10% to approximately 15-20% since 2024, with significant room for further penetration in the ~$60 million global SCIg market[11] Pipeline and Outlook - KORU Medical Systems has 7 collaborations/opportunities with Ig manufacturers, targeting a $450 million Total Ig TAM (Total Addressable Market)[12] - The company plans for 4 new drug additions on the KORU Freedom Infusion System by 2026, expanding internationally and pursuing drug labels independently, targeting a $1.8 billion Total TAM[13] - KORU Medical Systems is progressing with its strategic oncology infusion market entry initiative, with an anticipated market entry in 4Q25/1Q26, targeting a ~$138 million 2025 TAM[18, 19]

Financial Performance - Revenue in 3Q25 reached $1273 million, with a 121% organic growth at constant currency year-over-year[23] - Adjusted EBITDA margin was 185% in 3Q25[23] - Adjusted profit margin was 89% in 3Q25[23] - Cash generated from operating activities in 9M25 was $465 million, with an operating cash flow/adjusted EBITDA of 718%[72] - Adjusted diluted EPS in 3Q25 was $009, a 16% year-over-year increase[77] Growth and Expansion - CI&Ters grew by 163% year-over-year, reaching 7,858 employees[31, 33] - The company is expanding its people platform for growth[30] - The company has a diversified revenue base, with financial services contributing 36%, consumer goods 20%, retail and industrial goods 21%, tech and telecom 10%, life sciences 8%, and others 5% of the total revenue in 9M25[61] - Latin America accounts for 47%, North America 44%, and new markets 10% of the total revenue by geography in 9M25[61] AI and Technology - CI&T is driving AI adoption internally, with rapid growth in its library of agents and adoption by CI&Ters[35, 36] - 85% adoption across CI&Ters with 64% daily active CI&Ters[38, 39]

Financial Performance - Q1 FY2026 revenue reached $14883 million, up 8% year-over-year[9, 26, 32, 33] - Non-GAAP EPS was $1.00, a 10% increase year-over-year[9] - Non-GAAP gross margin was 68.1%[9] - Non-GAAP operating margin was 34.4%[9] AI Momentum - Cisco secured $1300 million in AI infrastructure orders from hyperscale customers in Q1 FY26[6, 9, 18] - AI orders of over $200 million were taken from neocloud, sovereign, and enterprise customers in Q1 FY26[6, 18] - The company anticipates over $3000 million in AI infrastructure revenues in FY26[6, 12] - The AI opportunities pipeline is growing, exceeding $2000 million across neocloud, sovereign, and enterprise customers[9, 15] Recurring Revenue - Total RPO increased by 7% year-over-year to $42900 million, with product RPO up 10% year-over-year[9, 27] - Total ARR grew by 5% year-over-year to $31400 million, with product ARR up 7% year-over-year[9, 27] Capital Allocation - Cisco returned $3600 million to shareholders in Q1 FY26, including $2001 million in share repurchases[9, 35]

Financial Performance & Growth - 2024 Revenue was $3.4 billion[14] - 2024 Adjusted EBITDA was $761 million[15] - 2024 Adjusted EPS was $1.39[22] - Q3 2025 Revenue reached $856 million, a 3% year-over-year increase[27] - Q3 2025 Adjusted EBITDA margin improved by 90 basis points year-over-year to 22.9%[28] - Q3 2025 Adjusted EPS increased by 18% year-over-year to $0.39[28] Market Opportunities & Strategy - The company anticipates double-digit core growth in growth markets[38] - The company expects Personal Mobility revenue to more than double by 2028, with a Compound Annual Growth Rate (CAGR) of approximately 30%[41, 58] - The company sees a potential revenue opportunity of approximately $100 million to $200 million by 2028 from liquid-cooled Data Center applications[58] Financial Targets & Outlook - The company is on track to deliver its mid-term Adjusted EBITDA margin target in 2027[50] - The company anticipates end markets to recover in 2026, driving incremental earnings growth[58]